Cargando…

Partial volume correction analysis for (11)C-UCB-J PET studies of Alzheimer’s disease

PURPOSE: (11)C-UCB-J PET imaging, targeting synaptic vesicle glycoprotein 2A (SV2A), has been shown to be a useful indicator of synaptic density in Alzheimer’s disease (AD). For SV2A imaging, a decrease in apparent tracer uptake is often due to the combination of gray-matter (GM) atrophy and SV2A de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yihuan, Toyonaga, Takuya, Naganawa, Mika, Gallezot, Jean-Dominique, Chen, Ming-Kai, Mecca, Adam P., van Dyck, Christopher H., Carson, Richard E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454285/ https://www.ncbi.nlm.nih.gov/pubmed/34119639 http://dx.doi.org/10.1016/j.neuroimage.2021.118248

Ejemplares similares

Principal component analysis of synaptic density measured with [(11)C]UCB-J PET in early Alzheimer’s disease
por: O'Dell, Ryan S., et al.
Publicado: (2023)

Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [(11)C]UCB‐J
por: Mecca, Adam P., et al.
Publicado: (2022)

Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [(11)C]UCB-J
por: O’Dell, Ryan S., et al.
Publicado: (2021)

Identifying brain networks in synaptic density PET ((11)C-UCB-J) with independent component analysis
por: Fang, Xiaotian T., et al.
Publicado: (2021)

Feasibility of imaging synaptic density in the human spinal cord using [(11)C]UCB-J PET
por: Rossano, Samantha, et al.
Publicado: (2022)

Drug characteristics derived from kinetic modeling: combined (11)C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A
por: Naganawa, Mika, et al.
Publicado: (2022)

Adaptive data-driven motion detection and optimized correction for brain PET
por: Revilla, Enette Mae, et al.
Publicado: (2022)

Potential of [(11)C]UCB-J as a PET tracer for islets of Langerhans
por: Puuvuori, Emmi, et al.
Publicado: (2021)

Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand (11)C-UCB-J
por: Bini, Jason, et al.
Publicado: (2020)

Validation and noninvasive kinetic modeling of [(11)C]UCB-J PET imaging in mice
por: Bertoglio, Daniele, et al.
Publicado: (2019)

(11)C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies
por: Nicastro, Nicolas, et al.
Publicado: (2020)

Validation and test–retest repeatability performance of parametric methods for [(11)C]UCB-J PET
por: Tuncel, Hayel, et al.
Publicado: (2022)

Human biodistribution and dosimetry of [(11)C]-UCB-J, a PET radiotracer for imaging synaptic density
por: Cawthorne, Christopher, et al.
Publicado: (2021)

In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET
por: Mecca, Adam P., et al.
Publicado: (2020)

Kinetics and 28-day test–retest repeatability and reproducibility of [(11)C]UCB-J PET brain imaging
por: Tuncel, Hayel, et al.
Publicado: (2020)

Linking resting-state network fluctuations with systems of coherent synaptic density: A multimodal fMRI and (11)C-UCB-J PET study
por: Fang, Xiaotian T., et al.
Publicado: (2023)

Synaptic density in carriers of C9orf72 mutations: a [(11)C]UCB‐J PET study
por: Malpetti, Maura, et al.
Publicado: (2021)

Molecular pathology and synaptic loss in primary tauopathies: an (18)F-AV-1451 and (11)C-UCB-J PET study
por: Holland, Negin, et al.
Publicado: (2021)

Improved synthesis of SV2A targeting radiotracer [(11)C]UCB-J
por: Rokka, Johanna, et al.
Publicado: (2019)

Assessment of population-based input functions for Patlak imaging of whole body dynamic (18)F-FDG PET
por: Naganawa, Mika, et al.
Publicado: (2020)

Automated radiosynthesis of [(11)C]UCB‐J for imaging synaptic density by positron emission tomography
por: Milicevic Sephton, Selena, et al.
Publicado: (2020)

Synaptic Loss in Frontotemporal Dementia Revealed by [ (11)C]UCB‐J Positron Emission Tomography
por: Malpetti, Maura, et al.
Publicado: (2022)

Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [(11)C]UCB-J PET study in a model of obsessive–compulsive disorder-like behaviour
por: Glorie, Dorien, et al.
Publicado: (2020)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

[(11)C]Methionine and [(11)C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis
por: Tran, Thuy T., et al.
Publicado: (2020)

PET Imaging in Animal Models of Alzheimer’s Disease
por: Chen, Baosheng, et al.
Publicado: (2022)

PET imaging of mGluR5 in Alzheimer’s disease
por: Mecca, Adam P., et al.
Publicado: (2020)

PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging
por: Toyonaga, Takuya, et al.
Publicado: (2022)

Partial volume correction for PET quantification and its impact on brain network in Alzheimer’s disease
por: Yang, Jiarui, et al.
Publicado: (2017)

Isoextraction Studies of Partition of UCB Between Chloroform and Aqueous Solution
por: Hahm, Joon Soo, et al.
Publicado: (1987)

Reducing the osteoporosis treatment gap: an interview with UCB's Pascale Richetta
por: Richetta, Pascale
Publicado: (2017)

Metabolic and amyloid PET network reorganization in Alzheimer’s disease: differential patterns and partial volume effects
por: Gonzalez-Escamilla, Gabriel, et al.
Publicado: (2020)

Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [(18)F]UCB-H PET imaging
por: Vogler, Letizia, et al.
Publicado: (2023)

2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PET
por: Radhakrishnan, Rajiv, et al.
Publicado: (2018)

Harmonization of [(11)C]raclopride brain PET images from the HR+ and HRRT: method development and validation in human subjects
por: Hoye, Jocelyn, et al.
Publicado: (2022)

Test-retest variability of adenosine A(2A) binding in the human brain with (11)C-TMSX and PET
por: Naganawa, Mika, et al.
Publicado: (2014)

Partial volume correction strategies for quantitative FDG PET in oncology
por: Hoetjes, Nikie J., et al.
Publicado: (2010)

The pharmacokinetics of [(18)F]UCB-H revisited in the healthy non-human primate brain
por: Goutal, Sébastien, et al.
Publicado: (2021)

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials
por: Van Dyck, Christopher H., et al.
Publicado: (2023)

The feasibility of (11)C‐PIB‐PET/CT for amyloid plaque burden: validation of the effectiveness of CT‐based partial volume correction
por: Sasaki, Kei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_59amqhqktfieaerfpalnn5451m